Inhibrx Biosciences (INBX) Equity Average (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Equity Average data on file, last reported at $22.4 million in Q4 2025.

• Equity Average for Q4 2025 came in at $22.4 million, down 85.64% year-over-year; the trailing twelve-month figure through Dec 2025 was $22.4 million (down 85.64% YoY), and the FY2025 annual result was $70.8 million, down 20.05% from the prior year.
• Equity Average eased to $22.4 million in Q4 2025 per INBX's latest filing, from $52.7 million in the prior quarter.
• Over five years, Equity Average peaked at $198.9 million in Q3 2024 and troughed at $22.4 million in Q4 2025.
• A 3-year average of $90.8 million and a median of $84.0 million in 2023 frame the typical range for Equity Average.
• On a YoY basis, Equity Average climbed as much as 314.06% in 2025 and fell as far as 85.64% in 2025.
• A 3-year view of Equity Average shows it stood at $86.5 million in 2023, then surged by 80.27% to $156.0 million in 2024, then slumped by 85.64% to $22.4 million in 2025.
• Business Quant data shows INBX's Equity Average at $22.4 million in Q4 2025, $52.7 million in Q3 2025, and $81.5 million in Q2 2025.